Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2016 Dec 2;291(49):25763. doi: 10.1074/jbc.A116.751362

Receptor activity-modifying protein-directed G protein signaling specificity for the calcitonin gene-related peptide family of receptors.

Cathryn Weston, Ian Winfield, Matthew Harris, Rose Hodgson, Archna Shah, Simon J Dowell, Juan Carlos Mobarec, David A Woodcock, Christopher A Reynolds, David R Poyner, Harriet A Watkins, Graham Ladds
PMCID: PMC5207273  PMID: 27913664

VOLUME 291 (2016) PAGES 21925–21944

PAGES 21931 AND 21933:

There were some errors in Tables 3 and 4 whereby some data values were increased by the addition of 10 units to each data point. These errors have now been corrected and do not affect the results or conclusions of this work.

TABLE 3.

Potency (pEC50), affinity (pKa) and coupling efficacy (log τ) values for cAMP production at the CLR co-expressed with each RAMP, stimulated with various agonists measured in HEK-293 cells in the presence and absence of pertussis toxin

Data are the mean ± S.E. of n individual data sets. Statistically different between PTX-treated and untreated was determined using Student's t test (*, p < 0.05; **, p < 0.01; ***, p < 0.001; and ****, p < 0.0001).

Untreated
Treated
pEC50a Emaxb pKac log τd n pEC50a Emaxb pKac log τd n
RAMP1
    CGRP 9.66 ± 0.2 47.07 ± 2.2 9.43 ± 0.2 −0.11 ± 0.04 9 9.65 ± 0.2 44.95 ± 2.2 9.33 ± 0.3 −0.11 ± 0.07 6
    AM 7.93 ± 0.2 48.06 ± 2.5 7.67 ± 0.2 −0.09 ± 0.05 9 8.14 ± 0.07 72.17 ± 1.7*** 7.66 ± 0.2 0.36 ± 0.1** 6
    AM2 7.93 ± 0.2 46.10 ± 4.1 7.70 ± 0.2 −0.11 ± 0.07 9 9.15 ± 0.1* 72.15 ± 2.4*** 8.56 ± 0.3 0.4 ± 0.1** 6

RAMP2
    CGRP 9.00 ± 0.2 36.97 ± 2.4 8.82 ± 0.2 −0.27 ± 0.05 9 8.25 ± 0.4 56.27 ± 1.4*** 7.92 ± 0.2* 0 0.1 ± 0.06** 6
    AM 10.35 ± 0.1 56.33 ± 1.6 10.00 ± 0.1 0.07 ± 0.02 9 10.16 ± 0.07 56.07 ± 1.1 9.83 ± 0.2 0.07 ± 0.02 6
    AM2 7.46 ± 0.2 36.61 ± 3.5 7.24 ± 0.2 −0.29 ± 0.07 9 9.13 ± 0.1** 56.05 ± 2.2*** 8.84 ± 0.2** 0.1 ± 0.06* 6

RAMP3
    CGRP 7.75 ± 0.3 22.38 ± 2.6 7.64 ± 0.3 −0.54 ± 0.07 8 8.90 ± 0.1* 32.61 ± 1.5* 8.74 ± 0.2* −0.29 ± 0.06 7
    AM 8.98 ± 0.2 32.00 ± 1.5 8.83 ± 0.1 −0.33 ± 0.03 8 9.10 ± 0.2 35.95 ± 2.2 8.94 ± 0.2 −0.34 ± 0.05 7
    AM2 9.10 ± 0.2 21.92 ± 1.7 9.08 ± 0.2 −0.51 ± 0.06 8 8.74 ± 0.2 44.35 ± 2.7**** 8.43 ± 0.1* −0.07 ± 0.07*** 7

a The negative logarithm of the agonist concentration required to produce a half-maximal response.

b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 μm forskolin stimulation in the presence of pertussis toxin treatment.

c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).

d Log τ is the coupling efficiency parameter of each ligand.

TABLE 4.

Potency (pEC50) and maximal response (Emax), for cAMP production at the CLR co-expressed with each RAMP, stimulated with various agonists measured in HEK-293S cells in the presence or absence of pertussis toxin

Data are the mean ± S.E. of n individual data sets. No statistical difference was found between untreated and PTX-treated HEK-293S cells using Student's t test.

Untreated
Treated
pEC50a Emaxb n pEC50a Emaxb n
RAMP1
    CGRP 9.88 ± 0.1 59.98 ± 1.1 5 9.87 ± 0.1 72.92 ± 2.3 5
    AM 8.13 ± 0.1 60.00 ± 3.1 5 8.03 ± 0.1 61.26 ± 2.6 5
    AM2 8.74 ± 0.1 68.94 ± 1.2 5 8.78 ± 0.1 68.30 ± 1.6 5

RAMP2
    CGRP 8.00 ± 0.1 32.56 ± 1.0 5 7.88 ± 0.1 39.32 ± 1.7 5
    AM 9.39 ± 0.1 30.34 ± 0.8 5 9.38 ± 0.1 33.28 ± 1.2 5
    AM2 8.57 ± 0.1 40.30 ± 1.5 5 8.58 ± 0.2 30.52 ± 2.0 5

RAMP3
    CGRP 8.42 ± 0.1 40.84 ± 0.6 5 8.38 ± 0.1 39.84 ± 1.0 5
    AM 9.63 ± 0.1 39.09 ± 1.2 5 9.49 ± 0.2 42.26 ± 1.6 5
    AM2 8.01 ± 0.1 33.75 ± 1.5 5 7.79 ± 0.2 28.21 ± 2.4 5

a The negative logarithm of the agonist concentration required to produce a half-maximal response.

b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 μm forskolin stimulation in the presence of PTX treatment.


Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES